Amnis Therapeutics

Company Overview

Snapshot

Founded in January 2007, Amnis Therapeutics operated with 1–10 employees, developing endovascular technologies. The company raised $400K across two funding rounds. In May 2017, MedTech Innovator led a funding round for Amnis Therapeutics.

Business overview

Amnis Therapeutics is a biomedical engineering company focused on developing, manufacturing, and marketing lifesaving endovascular technologies for emergency situations. The company provides innovative, high-performance devices for various endovascular indications, including its AneugraftDx, a pericardium covered coronary stent for acute rupture or dissection of a coronary artery, and AneugraftNx, a neurovascular pericardium covered stent for intracranial indications. Additionally, Amnis Therapeutics expanded its product development to include the Golden Retriever, a mechanical neurothrombectomy device for acute ischemic stroke. The company operates within the Health Tech & Life Sciences sector, serving the medical devices industry in markets across Asia and Europe.

Strategic signal

In January 2017, Amnis Therapeutics initiated its first clinical trial for its neuro thrombectomy device. This milestone signals the company's progression from product development to clinical validation, a critical step for medical device companies seeking regulatory approval and market entry. For investors, this indicates a move towards demonstrating efficacy and safety in a real-world setting, which is essential for future commercialization and adoption in the stroke treatment market.

Company Intelligence Q&A

What is Amnis Therapeutics' primary focus?

Amnis Therapeutics specializes in developing, manufacturing, and marketing lifesaving endovascular technologies for emergency situations, aiming to provide innovative solutions for various endovascular indications.

When did Amnis Therapeutics cease operations?

Amnis Therapeutics ceased to operate in July 2021.

What significant funding event occurred in May 2017?

In May 2017, Amnis Therapeutics received funding in a round led by.

What was a key product developed by Amnis Therapeutics?

One key product developed by Amnis Therapeutics is the Golden Retriever, a mechanical neurothrombectomy device designed for the emergency treatment of acute ischemic stroke.

What clinical milestone did Amnis Therapeutics achieve in January 2017?

In January 2017, Amnis Therapeutics started its first clinical trial with its neuro thrombectomy device.